WO2000042955A1 - Drug dosage unit for buccal administration of steroidal active agents - Google Patents
Drug dosage unit for buccal administration of steroidal active agents Download PDFInfo
- Publication number
- WO2000042955A1 WO2000042955A1 PCT/US2000/001546 US0001546W WO0042955A1 WO 2000042955 A1 WO2000042955 A1 WO 2000042955A1 US 0001546 W US0001546 W US 0001546W WO 0042955 A1 WO0042955 A1 WO 0042955A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage unit
- acetate
- estradiol
- progestin
- estrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Definitions
- This invention relates generally to pharmaceutical compositions and methods for administering pharmacologically active agents. More particularly, the invention relates to buccal drug delivery, and to a buccal dosage unit and method for administering a combination of steroidal active agents, e.g., for female hormone replacement therapy, female contraception, treatment of female sexual dysfunction, and the like.
- Androgens are the hormones that cause most of the masculinizing changes that occur in males during puberty. Harrison 's Principles of Internal Medicine, 12 th Edition (New York, NY: McGraw Hill, Inc., 1991). However, low levels of androgens are also present in normal females. Testosterone and other androgens are secreted by the ovary and the adrenal cortex. See, e.g., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9 th Edition (New York, NY: McGraw Hill, Inc., 1996). Dehydroepiandrosterone (DHEA) and androstenedione are also synthesized by both the adrenal gland and the ovary and can be converted to testosterone or estrogen in peripheral tissues.
- DHEA Dehydroepiandrosterone
- androstenedione are also synthesized by both the adrenal gland and the ovary and can be converted to testosterone or estrogen in peripheral tissues.
- Dyspareunia is thought to affect approximately 40% of women; it has been estimated that over 40 million female individuals will suffer dyspareunia at some time in their lives. On the order of twenty-five million women will experience dyspareunia in the peri- and postmenopausal periods (Kelly (1992) Clinical Practice and Sexuality 8(8):2; and Sato et al. ( 1992) Clinical Practices in Sexuality 8(5) : 1.
- Estrogen therapy is commonly used in the pharmacological treatment of altered hormone profiles or sexual dysfunction in women.
- Estrogen-based therapies are generally used to increase mucous production, provide vasodilator effects, and/or to increase the general health of the vagina.
- estrogen is administered orally, parenterally (e.g., by injection), or topically.
- parenterally e.g., by injection
- With oral administration as is true with the oral administration of many steroid hormones, estrogens tend to be inactivated; estradiol, for example, is converted to estriol and estrone and then conjugated to glucuronic acid or sulfate.
- estrogens also impair hepatic secretory activity. This "first pass" effect may lead to an undesirable increase in the production of certain coagulation factors and other biologically important compounds by the liver.
- Parenterally administered estrogen avoids the aforementioned problems associated with oral administration.
- all estrogen-based therapies are known to increase the risk of endometrial hyperplasia and cancer, as well as the risk of breast cancer, in treated individuals. Because of the increased risk of endometrial hyperplasia and endometrial cancer encountered with unopposed estrogen therapies, estrogen/ progestin combinations have been employed.
- such therapies result in a number of side effects, including uterine bleeding and the continuation of menstrual periods. Accordingly, there remains a need in the art to provide safer and more effective treatments for administering active agents suitable for female hormone replacement therapy.
- the present invention is directed in part to the aforementioned need in the art, and provides highly effective hormone replacement therapy for women in need of such treatment.
- the invention involves the use of a pharmaceutical composition in the form of a drug dosage unit to be applied to the buccal mucosa.
- the present invention avoids both gastrointestinal degradation of the drug and the "first pass" effect in the liver encountered with oral formulations, and enables the use of smaller doses of active agents (and thus avoids the side effects associated with conventional formulations).
- an androgenic agent is included, as in the preferred embodiment herein, essentially complete hormone replacement is provided.
- estrogen/progestin therapies do not in fact provide "replacement" of the complete hormone profile of the premenopausal woman, because, as discussed above, androgens are also present in premenopausal women.
- the present invention calls for one or more androgenic agents to be administered along with a progestin and an estrogen.
- the method and compositions of the invention may also be used to treat other conditions for which the disclosed hormone combination is useful.
- the novel drug dosage units can be used to treat female sexual dysfunction, to effect female contraception, to improve vaginal muscle tone and tissue health, and to enhance vaginal lubrication. Drug therapy for treating female sexual dysfunction has been described. For example,
- U.S. Patent No. 4,507,323 to Stern describes the use of the anxiolytic w-chloro- ⁇ -t- butylamino-propiophenone in the treatment of sexual dysfunction in male and female individuals.
- Pharmaceutical compositions containing the agent are described, which are presented in discrete units, e.g., cachets, tablets, capsules, ampules and suppositories for oral or anal delivery of the agent.
- U.S. Patent No. 4,521,421 to Foreman describes the treatment of sexual dysfunction in male and female individuals using the stereoisomers of octahydro-pyrimidoquinoline agents, centrally acting dopamine agonists.
- U.S. Patent No. 5,190,967 to Riley describes the treatment of sexual disorders in male and female individuals using heterocyclic benzodioxinopyrrole compounds, which, like the drugs described in the aforementioned patents, are centrally acting agents.
- U.S. Patent No. 4,755,386 to Hsiao et al. generally describes the buccal administration of various medicaments, including estrogens, progestins and androgens; combinations of the medicaments, however, are not contemplated.
- the buccal tablets of Hsiao et al. weighing on the order of 50 mg, contain adhesive, disintegrant and excipient in addition to the active agent, with the inactive ingredients representing up to about 90 wt.% of the formulation.
- the buccal drug dosage units and methods of the present invention are, however, new and completely unsuggested by the art.
- Applicants' invention is premised on the discovery that steroidal agents, particularly an androgenic agent in combination with an estrogen and a progestin, can be buccally administered to provide for a highly effective method of female hormone replacement therapy.
- the buccal dosage units provided herein can also be used for other purposes, e.g., treatment of female sexual dysfunction, female contraception, improvement of vaginal muscle tone and tissue health, enhancement of vaginal lubrication, and the like.
- a drug dosage unit for buccally administering to a female individual a pharmaceutical composition comprising an estrogenic agent and a progestin, optionally in further combination with an androgenic agent.
- a pharmaceutical composition in the form of a simple, compact buccal dosage unit comprising therapeutically effective amounts of an androgenic agent, a progestin and an estrogen, or therapeutically effective amounts of an estrogen and a progestin, in a bioerodible polymeric carrier, wherein the carrier is such that it enables the dosage unit to adhere to the buccal mucosa. Following application to the buccal mucosa, gradual and complete erosion of the unit occurs over a predetermined time period, thus providing drug delivery throughout that time period.
- the dosage unit contains only the active agents to be administered and the polymeric carrier.
- the dosage units are designed to erode and thus deliver the active agents over a predetermined time period that is generally in the range of about 8 hours to about 24 hours, 12-hour dosage units are preferred, such that the individual receiving drug therapy can conveniently use two dosage units in a 12-hour period, enabling two "breaks" for dental hygiene or the like during the day.
- the dosage units can be applied to an area of a subject's buccal mucosa such that the subject can eat and/or drink with the unit in place.
- a method for administering a combination of steroidal agents to a female individual using the aforementioned buccal dosage units, to treat any disorder, condition, disease or dysfunction for which the combination of an estrogen, a progestin. and. optionally, an androgenic agent, be indicated.
- the combination of active agents may be administered, for example, to provide female hormone replacement therapy, to effect female contraception, to treat female sexual dysfunction, to improve vaginal muscle tone and tissue health, to enhance vaginal lubrication, and the like.
- the active agents are administered through the buccal mucosa by affixing a dosage unit as provided herein to the buccal mucosa of the individual undergoing treatment, and allowing the dosage unit to remain in place until erosion thereof and thus drug delivery is complete.
- the dosage unit is affixed to the upper gum area in a region defined as extending from the first bicuspid on the left to the first bicuspid on the right; an alternative preferred location for the dosage unit is the inner lip area opposing the aforementioned gum area.
- kits for assisting an individual in buccal drug administration includes the following components: a buccal dosage unit comprising a combination of steroidal active agents in a bioerodible polymeric carrier; a container housing the dosage unit prior to use; and written instructions for carrying out administration of the active agents for the intended therapeutic purpose.
- Figure 1 schematically illustrates one embodiment of a buccal dosage unit according to the invention.
- Figure 2 schematically illustrates an alternative and preferred embodiment of a buccal dosage unit according to the invention.
- drug or “pharmacologically active agent” or “active agent” are used interchangeably herein to refer to a compound or composition of matter which, when administered to an organism (human or animal) induces a desired pharmacologic and/or physiologic effect by local and/or systemic action.
- active agents herein are steroid hormones, including androgenic agents, e.g., testosterone and derivatives, analogs, esters and salts thereof, progestins (also referred to herein and in the art as “progestogens”), e.g., progesterone and the like, and estrogens, e.g., ethynyl estradiol and the like.
- buccal drug delivery is meant delivery of a drug by passage of a drug through the buccal mucosa into the bloodstream.
- buccal drug delivery is effected herein by placing the buccal dosage unit on the upper gum or opposing inner lip area of the individual undergoing drug therapy.
- Poration enhancement or “permeation enhancement” as used herein relates to an increase in the permeability of the buccal mucosal tissue to a pharmacologically active agent, i.e., so that the rate at which the drug permeates through the mucosal tissue is increased.
- Excipients or “vehicles” as used herein refer to any excipients or vehicles suitable for buccal drug administration, and include any such materials known in the art, e.g., any liquid, gel, solvent, liquid diluent, solubilizer, or the like, which is nontoxic and does not interact with other components of the composition in a deleterious manner.
- an “effective” or “therapeutically effective” amount of a drug or pharmacologically active agent is meant a nontoxic but sufficient amount of the drug or agent to provide the desired effect.
- An “effective” amount of a permeation enhancer as used herein means an amount that will provide the desired increase in the rate at which an active agent passes through the tissue of the buccal mucosa.
- Compact refers to a buccal dosage unit that is preferably no larger than about 5 mm in diameter and 2 mm in height, so that the unit occupies at most about 40 mm 3 , typically weighs less than about 40 mg (preferably 5 to 20 mg, more preferably 10 to 15 mg), and has a contact surface area of no more than approximately 20 mm 3 .
- electrodes and “bioerodible” as used herein refer to a compound or composition that hydrolyzes upon contact with the buccal mucosa.
- female sexual dysfunction any and all types of sexual dysfunction in human females, including, but not limited to, excitement stage dysfunctions such as touch sensation impairment, loss of clitoral sensation, and vaginal dryness and concomitant dyspareunia.
- excitement stage dysfunctions such as touch sensation impairment, loss of clitoral sensation, and vaginal dryness and concomitant dyspareunia.
- Other types of female sexual dysfunction are discussed in detail by Kaplan, The Evaluation of Sexual Disorders: Psychological and Medical Aspects (New York, NY: Brunner-Mazel, 1983), and by Kolodny et al., Textbook of Sexual Medicine (Boston, MA: Little, Brown & Co., 1979). Reference may be had to those texts for information not explicitly discussed herein.
- treating and “treatment” as used herein refer to reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, prevention of the occurrence of symptoms and/or their underlying cause, and improvement or remediaton of damage.
- the present method of "treating" female sexual dysfunction encompasses both prevention of female sexual dysfunction and treatment of the dysfunction in a clinically symptomatic individual.
- a pharmaceutical composition in the form of a buccal dosage unit for the administration of a combination of steroidal agents.
- the dosage unit comprises (a) therapeutically effective amounts of an androgenic agent, a progestin and an estrogen, or of a progestin and an estrogen, and (b) a bioerodible polymeric carrier as will be described in detail below.
- the dosage unit is fabricated so as to erode gradually over a predetermined time period, wherein drug delivery is provided essentially throughout.
- the novel dosage unit avoids the disadvantages encountered with oral drug administration, e.g., degradation of the agents by fluids present in the gastrointestinal tract and/or first-pass inactivation in the liver.
- the unit is not associated with the discomfort encountered with larger, conventional buccal drug delivery systems.
- the units are convenient in that the wearer need change the unit only once or twice daily, i.e., with 24-hour or 12-hour systems, respectively; a 12-hour unit to be applied once in the morning and once in the evening is optimal.
- the unit contains only the active agents and the polymeric carrier— manufacture of the dosage form is straightforward and economical.
- the buccal dosage units of the invention are useful in providing effective female hormone replacement therapy, in that the occurrence of symptoms or conditions resulting from altered hormone levels is mitigated or substantially prevented.
- the invention is thus useful to treat women for whom ovarian steroid production has been altered, either because of menopause, surgical or radiation treatment, ovarian ablation, or premature ovarian failure.
- the invention is also useful to treat female sexual dysfunction, to effect female contraception, to improve vaginal muscle tone and tissue health, and for enhancing vaginal lubrication.
- Each buccal dosage unit will contain an androgenic agent, a progestin. and an estrogen, or a progestin and an estrogen.
- Suitable androgenic agents that may be used in the formulations of the present invention include, but are not limited to: the naturally occurring androgens and derivatives thereof, including androsterone, androsterone acetate, androsterone propionate, androsterone benzoate, androstenediol, androstenediol-3 -acetate, androstenediol-17-acetate, androstenediol-3 , 17-diacetate, androstenediol- 17-benzoate, androstenediol-3 -acetate- 17- benzoate, androstenedione.
- the naturally occurring androgens and derivatives thereof including androsterone, androsterone acetate, androsterone propionate, androsterone benzoate, androstenediol, androstenediol-3 -acetate, androstenediol-17-acetate, androstenediol-3 , 17-diacetate, androst
- esters of testosterone and 4-dihydrotestosterone typically esters formed from the hydro xyl group present at the C-17 position, including, but not limited to, the enanthate, propionate, cypionate, phenylacetate, acetate, isobutyrate.
- testosterone esters such as methyl testosterone, testolactone, oxymetholone and fluoxymesterone.
- Testosterone and testosterone esters such as testosterone enanthate. testosterone propionate and testosterone cypionate. are particularly preferred androgenic agents for use in conjunction with the present invention.
- the aforementioned testosterone esters are commercially available or may be readily prepared using techniques known to those skilled in the art or described in the pertinent literature.
- the 17-hydroxyl group of the testosterone molecule is caused to react with a suitable organic acid under esterifying conditions, such conditions typically involving the use of a strong acid such as sulfuric acid, hydrochloric acid, or the like, and a temperature sufficient to allow the reaction to proceed at reflux.
- Suitable estrogens that may be administered using the dosage units of the invention include synthetic and natural estrogens such as: estradiol (i.e., l,3.5-estratriene-3,17 ⁇ -diol, or " ⁇ -estradiol") and its esters, including estradiol benzoate, valerate, cypionate, heptanoate, decanoate, acetate and diacetate; 17 ⁇ -estradiol; ethynylestradiol (i.e., 17 ⁇ -ethynylestradiol) and esters and ethers thereof, including ethynylestradiol 3-acetate and ethynylestradiol 3- benzoate; estriol and estriol succinate; polyestrol phosphate; estrone and its esters and derivatives, including estrone acetate, estrone sulfate.
- estradiol i.e., l,3.5-estratriene-3,17 ⁇
- estrone sulfate quinestrol; mestranol; and conjugated equine estrogens.
- Estradiol and ethynylestradiol are particularly preferred synthetic estrogenic agents for use in conjunction with the present invention.
- Suitable progestins for use in the buccal drug delivery units of the invention include, but are not limited to, acetoxypregnenolone, allylestrenol, anagestone acetate, chlormadinone acetate, cyproterone, cyproterone acetate, desogestrel, dihydrogesterone, dimethisterone, ethisterone (17 ⁇ -ethynyltestosterone), ethynodiol diacetate, flurogestone acetate, gestadene, hydroxyprogesterone, hydroxyprogesterone acetate, hydroxyprogesterone caproate, hydroxymethylprogesterone, hydroxymethylprogesterone acetate, 3-ketodesogestrel, levonorgestrel, lynestrenol, medrogestone, medroxyprogesterone acetate, megestrol, megestrol acetate, melengestrol acetate, nore
- the aforementioned steroidal agents are selected from the group consisting of naturally occurring steroids, synthetic steroids, and derivatives thereof.
- the active agents may be incorporated into the present dosage units and thus administered in the form of a pharmaceutically acceptable derivative, analog, ester or salt, or the agents may be modified by appending one or more appropriate functionalities to enhance selected biological properties such as penetration through the mucosal tissue.
- esters are preferred relative to salts or other derivatives. Preparation of esters involves functionalization of hydroxyl and/or carboxyl groups that may be present, as will be appreciated by those skilled in the arts of pharmaceutical chemistry and drug delivery. Esters can be reconverted to the free acids, if desired, by using conventional hydrogenolysis or hydrolysis procedures.
- suitable pharmaceutically acceptable salts can be prepared using standard procedures known to those skilled in the art of synthetic organic chemistry and described, for example, by J. March, Advanced Organic
- Acid addition salts are prepared from an active agent in the free base form (e.g., compounds having a neutral -NH-, group) using conventional means, involving reaction with a suitable acid.
- Suitable acids for preparing acid addition salts include both organic acids, e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like, as well as inorganic acids, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
- organic acids e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic
- the drug may be incorporated into the present dosage units either as the racemate or in enantiomerically pure form.
- each active agent in the buccal dosage unit will depend on a number of factors, including the potency of each agent and the intended dosage, which, in turn, is dependent on the particular individual undergoing treatment, the specific indication, and the like.
- the androgenic agent represents approximately 5 wt.% to 20 wt.%, preferably 10 wt.% to 20 wt.%, of the buccal dosage unit
- the progestin represents approximately 5 wt.% to 60 wt.%, preferably 30 wt.% to 60 wt.%, of the dosage unit
- the estrogen represents approximately 1 wt.% to 5 wt.%, preferably 2 wt.% to 5 wt.%, of the buccal dosage unit.
- the remainder of the buccal dosage unit comprises the bioerodible polymeric carrier, as will be described in detail below, and any excipients that may be desired, e.g., binders, disintegrants, lubricants, diluents, flavorings, colorings, and the like, and/or additional active agents.
- the carrier comprises a polymer having sufficient tack to ensure that the dosage unit adheres to the buccal mucosa for the necessary time period, i.e., the time period during which the combination of active agents is to be delivered to the buccal mucosa.
- the polymeric carrier is preferably sticky when moist, but not when dry. for convenience in handling.
- M w weight average molecular weight of the polymer be in the range of approximately 4,000 to 1,000,000, more preferably in the range of approximately 100,000 to 1,000,000.
- M w weight average molecular weight
- any polymeric carriers can be used that are pharmaceutically acceptable, provide both a suitable degree of adhesion and the desired drug release profile, and are compatible with the agents to be administered and any other components that may be present in the buccal dosage unit.
- the polymeric carriers comprise hydrophilic (water-soluble and water- swellable) polymers that adhere to the wet surface of the buccal mucosa.
- examples of polymeric carriers useful herein include acrylic acid polymers and copolymers, e.g., those known as "carbomers” (Carbopol®, which may be obtained from B.F. Goodrich, is one such polymer).
- polymers include, but are not limited to: hydrolyzed polyvinylalcohol; polyethylene oxides (e.g., Sentry Polyox® water soluble resins, available from Union Carbide); polyacrylates (e.g., Gantrez®, which may be obtained from GAF); vinyl polymers and copolymers; polyvinylpyrrolidone; dextran; guar gum; pectins; starches; and cellulosic polymers such as hydroxypropyl methylcellulose (e.g., Methocel®, which may be obtained from the Dow Chemical Company), hydroxypropyl cellulose (e.g., Klucel®, which may also be obtained from Dow), hydroxypropyl cellulose ethers (see, e.g., U.S.
- hydrolyzed polyvinylalcohol polyethylene oxides (e.g., Sentry Polyox® water soluble resins, available from Union Carbide); polyacrylates (e.g., Gantrez®,
- the carrier may also comprise two or more suitable polymers in combination, for example, a carbomer combined in an approximately 1 :5 to 5:1 ratio, by weight, with a polyethylene oxide.
- the present dosage unit contain only the active agents and the polymeric carrier. However, it may be desirable in some cases to include one or more additional components.
- a lubricant may be included to facilitate the process of manufacturing the dosage units; lubricants may also optimize erosion rate and drug flux. If a lubricant is present, it will represent on the order of 0.01 wt.% to about 2 wt.%, preferably about 0.01 wt.%) to 0.5 wt,%, of the dosage unit.
- Suitable lubricants include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, sodium stearylfumarate, talc, hydrogenated vegetable oils and polyethylene glycol.
- Such additional optional components include, for example, one or more disintegrants, diluents, binders, enhancers, or the like.
- disintegrants examples include, but are not limited to, cross-linked polyvinylpyrrolidones, such as crospovidone (e.g., Polyplasdone® XL, which may be obtained from GAF), cross-linked carboxylic methylcelluloses, such as croscarmelose (e.g., Ac-di-sol®, which may be obtained from FMC), alginic acid, and sodium carboxymethyl starches (e.g., Explotab®, which may be obtained from Edward Medell Co., Inc.), agar bentonite and alginic acid.
- cross-linked polyvinylpyrrolidones such as crospovidone (e.g., Polyplasdone® XL, which may be obtained from GAF)
- cross-linked carboxylic methylcelluloses such as croscarmelose (e.g., Ac-di-sol®, which may be obtained from FMC)
- alginic acid and sodium carboxymethyl starches
- Suitable diluents are those which are generally useful in pharmaceutical formulations prepared using compression techniques, e.g., dicalcium phosphate dihydrate (e.g., Di-Tab®, which may be obtained from Stauffer), sugars that have been processed by cocrystallization with dextrin (e.g., co-crystallized sucrose and dextrin such as Di-Pak®, which may be obtained from Amstar), lactone, calcium phosphate, cellulose, kaolin, mannitol, sodium chloride, dry starch, powdered sugar and the like. Binders, if used, are those that enhance adhesion.
- dicalcium phosphate dihydrate e.g., Di-Tab®, which may be obtained from Stauffer
- dextrin e.g., co-crystallized sucrose and dextrin such as Di-Pak®, which may be obtained from Amstar
- lactone e.g., co-crystallized sucrose and dex
- binders include, but are not limited to, starch, gelatin and sugars such as sucrose, dextrose, molasses, and lactose.
- Permeation enhancers may also be present in the novel dosage units in order to increase the rate at which the active agents pass through the buccal mucosa.
- permeation enhancers include, but are not limited to, dimethylsulfoxide (“DMSO”), dimethyl formamide (“DMF”), N,N-dimethylacetamide (“DMA”), decylmethylsulfoxide (“Q 0 MSO”), polyethylene glycol monolaurate (“PEGML”), glycerol monolaurate, lecithin, the 1 -substituted azacycloheptan-2-ones, particularly l- «-dodecylcyclazacycloheptan-2-one (available under the trademark Azone® from Nelson Research & Development Co., Irvine, CA), lower alkanols (e.g., ethanol), SEPA® (available from Macrochem Co., Lexington, MA), cholic acid, taurocholic acid, bile salt type enhancers, and surfactants such as Tergitol®, Nonoxynol- 9® and TWEEN-80®.
- Preferred dosage units of the invention do not contain permeation
- Flavorings are not typically needed in the present drug dosage units, as the active agents do not, in general, have any taste. If for some reason a flavoring is desired, any suitable flavoring may be used, e.g., mannitol, lactose or artificial sweeteners such as aspartame. Coloring agents may be added, although again, such agents are not required.
- coloring agents include any of the water soluble FD&C dyes, mixtures of the same, or their corresponding lakes.
- the present dosage units may be formulated with one or more preservatives or bacteriostatic agents, e.g., methyl hydroxybenzoate, propyl hydroxybenzoate, chlorocresol, benzalkonium chloride, or the like.
- preservatives or bacteriostatic agents e.g., methyl hydroxybenzoate, propyl hydroxybenzoate, chlorocresol, benzalkonium chloride, or the like.
- a method for administering a combination of steroidal agents using the buccal dosage units described hereinabove, containing an androgenic agent, a progestin. and an estrogen, or a progestin and an estrogen.
- the method generally comprises buccally administering the combination of active agents by affixing the dosage unit of the invention to the buccal mucosa of the individual and allowing the dosage unit to remain in place until erosion thereof— and thus drug delivery— is complete.
- the buccal administration of the aforementioned combinations of steroidal agents may be used in female hormone replacement therapy, so that the symptoms or conditions resulting from altered hormone levels is mitigated or substantially prevented.
- the method is also useful in other contexts, e.g., treatment of female sexual dysfunction, effecting female contraception, improving vaginal muscle tone and tissue health, and enhancing vaginal lubrication.
- the buccal dosage units and present method of administering active agents therewith are in addition useful to treat other conditions and disorders that are responsive to buccal administration of the combination of active agents disclosed herein.
- the invention is useful to treat the symptoms of premenstrual stress, osteoporosis, dry eye, the wasting syndrome accompanying AIDS (e.g., unintentional weight loss, decrease in lean body mass) and some autoimmune diseases, including but not limited to Sjogren's syndrome (see, e.g., U. S. Patent No. 5,639,743).
- AIDS e.g., unintentional weight loss, decrease in lean body mass
- some autoimmune diseases including but not limited to Sjogren's syndrome (see, e.g., U. S. Patent No. 5,639,743).
- the woman undergoing treatment will generally be of childbearing age or older, in whom ovarian estrogen, progesterone and androgen production has been interrupted either because of natural menopause, surgical procedures, radiation, chemical ovarian ablation or extirpation, or premature ovarian failure.
- Preferred dosage units for hormone replacement therapy are capable of delivering about 0.1 to about 2.5 mg of the selected androgenic agent, preferably testosterone or a testosterone ester, e.g., testosterone enanthate, cypionate or propionate, about 300 to 5000 ⁇ g progestin, e.g., norethindrone, norethindrone acetate or the like, and about 50 to 500 ⁇ g estrogen, e.g., estradiol, ethynyl estradiol or the like, over a period of about 24 hours.
- the selected androgenic agent preferably testosterone or a testosterone ester, e.g., testosterone enanthate, cypionate or propionate
- progestin e.g., norethindrone, norethindrone acetate or the like
- estrogen e.g., estradiol, ethynyl estradiol or the like
- the desired dose of each individual active agent will depend on the specific active agent as well as on other factors; the minimum effective dose of each active agent is of course preferred.
- the androgenic agent when present represents 5 wt.% to 20 wt.%, preferably 10 wt.% to 20 wt.%, of the buccal dosage unit
- the progestin represents approximately 5 wt.% to 60 wt.%, preferably 30 wt.% to 60 wt.%, of the dosage unit
- the estrogen represents approximately 1 wt.% to 5 wt.%, preferably 2 wt.% to 5 wt.%, of the buccal dosage unit.
- the buccal dosage units are preferably used consecutively so that administration of the active agents is substantially continuous.
- Buccal drug administration according to the invention provides highly effective female hormone replacement therapy. That is, the incidence and severity of hot flashes and night sweats are reduced, postmenopausal loss of calcium from bone is minimized, the risk of death from ischemic heart disease is reduced, and the vascularity and health of the vaginal mucosa and urinary tract are improved. At the same time, the side effects normally expected and encountered with conventional hormone replacement are minimized or eliminated.
- the dosage and administration period will, again, vary depending on the individual and the severity of sexual dysfunction or other condition; however, in general, the preferred dosage and treatment regimen is as described above for hormone replacement therapy.
- the dosage units may have any of the conventional shapes, for example, lozenges, disks, wafers, tablets or the like.
- One possible configuration is a conventional tablet shape as shown in Figure 1, with the dosage unit indicated generally at 10, the pharmaceutical composition er se shown at 12, and the dosage unit's two parallel substantially planar surfaces shown at 14 and 16; either surface can be used to affix the unit to the buccal mucosa.
- Figure 2 A more preferred configuration is shown in Figure 2, wherein the dosage unit is shown generally at 18 with the composition at 20, and the two opposing concave surfaces at 22 and 24; the opposing concave surfaces allow for a suction effect and improve adhesion of the unit to the mucosal tissue. It will be appreciated, of course, that only one of the two surfaces need be concave to achieve the desired suction effect.
- a less preferred configuration is shown in Figure 3, wherein the dosage unit shown generally at 26, containing pharmaceutical composition 28, has opposing convex surfaces 30 and 32.
- the dosage unit should have dimensions which fit conveniently into the buccal cavity. and, as emphasized elsewhere herein, is preferably quite compact.
- suitable dimensions for the dosage unit are 2 mm to about 5 mm in diameter, preferably not exceeding about 5 mm in diameter, and about 0.3 to about 2 mm in thickness, preferably about 0.5 to 1.5 mm in thickness, most preferably about 0.5 to 1.1 mm in thickness.
- the total weight of the dosage unit may be from about 5 mg to about 20 mg. preferably 10 mg to about 15 mg.
- the buccal dosage units may also be generated by a molding process.
- the final unit should have a melting point which is high enough to prevent fusion of packaged dosage units during shipping and storage, yet low enough to permit mixing of pharmaceutical ingredients without significant decomposition of the active agents when being incorporated into the molten carrier.
- the preferred position for placement of the dosage unit in the buccal cavity, as illustrated in Figure 4. is in the oral vestibule, generally indicated at 40, on the anterior surface 42 of the gum, between the marginal gingiva 44 and the reflexion of the mucosa from the lips to the gums 46, i.e., the dosage unit 48 is preferably attached to the alveolar mucosa 50, between the two bicuspids 52 and 54 and slightly to one side of the medial plane defined thereby.
- Such positioning places the dosage unit in contact with the mucosa on the internal surface of the lips 56 as well as the alveolar mucosa 50.
- Such placement provides advantages for optimal drug delivery.
- the dosage unit when so positioned, is out of the salivary flow path and is less likely to detach from the gum when the subject eats or drinks. Being out of the salivary flow path allows optimal direct transmucosal delivery of the active agents, any saliva that contacts the unit resulting not in dissolution of the active agents but, primarily, in softening the carrier. In addition, positioning the dosage unit as described minimizes mobility of the active agents in the mouth. Furthermore, the dosage unit will be in contact with both the alveolar mucosa and the internal mucosal surface of the lips, resulting in hydrolysis of the carrier, and thus absorption of the active agents through mucosa, on both sides of the tablet.
- the invention also encompasses a kit for patients to carry out the aforementioned methods.
- the kit contains the drug to be administered in a buccal dosage unit (e.g., as shown in Figures 1, 2 or 3), a sealed container housing the dosage unit prior to use, and written instructions for drug administration.
- Buccal dosage units weighing approximately 10 mg each and containing testosterone, estradiol and progesterone as the active agents were prepared using a tablet direct press, as follows.
- All components i.e., testosterone, estradiol, polyethylene oxide, carbomer, and magnesium stearate, as set forth in the above table
- the individual dosage units were then made by applying 10 mg of the mixture into the punch die of the tablet press, and compressing the mixed components using a pressure in the range of approximately 500 to 2000 psi. Tablets having a diameter of approximately 4 mm and a height of 1 mm were prepared. The tablets were removed from the punch die and the weight and dimensions of the tablets were measured.
- Buccal dosage units weighing approximately 10 mg each and containing testosterone, ethynyl estradiol and progesterone as the active agents, were prepared using a tablet direct press, as follows.
- All components i.e., testosterone, ethynyl estradiol, polyethylene oxide, carbomer, and magnesium stearate, as set forth in the above table
- aqueous fluid bed granulation to provide a homogeneous mixture of active agents and excipients.
- the individual dosage units were then made by applying approximately 10 mg of the mixture into the punch die of the tablet press, and compressing the mixed components using a pressure in the range of approximately 500 to 2000 psi. Tablets having a diameter of approximately 4 mm and a height of 1 mm were prepared. The tablets were removed from the punch die and the weight and dimensions of the tablets were measured.
- EXAMPLE 3 Female patients in need of hormone replacement may be administered the buccal dosage unit described in Example 1 or Example 2 every 24-hour period. Plasma levels of androgen, progestin and estrogen are measured using conventional methodology, both prior to treatment and at intervals after the start of treatment. The change in steroid hormone levels prior to and following treatment may be used to assess the efficacy of the hormone supplement. Based on these measurements, a determination is made as to whether or not hormone levels have reached acceptable levels. The individuals' dosage may be adjusted accordingly.
- EXAMPLE 4 Individual women are assessed and pre-screened to assemble an experimental group of subjects suffering from sexual dysfunction.
- the buccal drug dosage units of Examples 1 and 2 are each assessed in the experimental subjects for their ability to increase uterine or vaginal epithelial blood flow. Changes in blood flow or vaginal fluid production during and following buccal drug administration are determined using known methods. Increase in vaginal epithelial blood flow is determined using indirect methods such as photoplethysmography (Levin (1980) Clinics in Obstet. Gynaecol. 7:213-252), heated oxygen electrode (Wagner et al. (1978), "Vaginal Fluid” in The Human Vagina, Evans et al.
- vaginal dryness and/or dyspareunia are negatively correlated with vaginal blood flow rates, wherein increased blood flow to the vagina correlates with increased lubrication and decreased frequency and severity of dyspareunia (Sarrel (1990) Obstet. Gynaecol. 75:26S-32S). Accordingly, vulvar blood flow after treatment is assessed using laser Doppler velocimetry and compared to baseline levels. Increased vaginal lubrication as a result of treatment with the vasodilating formulations can also be assessed using the methods of Semmens et al. (1982) J. Am. Pled. Assoc. 248:445-448.
- the buccal dosage units of the invention including the units formulated as set forth in Examples 1 and 2, substantially increase blood flow to the vagina and vulvar area and alleviate vaginal dryness, as may be confirmed using the aforementioned methods.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU25139/00A AU2513900A (en) | 1999-01-26 | 2000-01-21 | Drug dosage unit for buccal administration of steroidal active agents |
EP00903386A EP1150629A4 (en) | 1999-01-26 | 2000-01-21 | Drug dosage unit for buccal administration of steroidal active agents |
CA002359587A CA2359587A1 (en) | 1999-01-26 | 2000-01-21 | Compact dosage unit for buccal administration of steroidal active agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/237,713 US6117446A (en) | 1999-01-26 | 1999-01-26 | Drug dosage unit for buccal administration of steroidal active agents |
US09/237,713 | 1999-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000042955A1 true WO2000042955A1 (en) | 2000-07-27 |
Family
ID=22894847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/001546 WO2000042955A1 (en) | 1999-01-26 | 2000-01-21 | Drug dosage unit for buccal administration of steroidal active agents |
Country Status (5)
Country | Link |
---|---|
US (5) | US6117446A (en) |
EP (1) | EP1150629A4 (en) |
AU (1) | AU2513900A (en) |
CA (1) | CA2359587A1 (en) |
WO (1) | WO2000042955A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002040008A2 (en) * | 2000-11-17 | 2002-05-23 | Warner-Lambert Company Llc | Treatment of sexual dysfunction with non peptide bombesin receptor antagonists |
WO2002058706A2 (en) * | 2000-12-22 | 2002-08-01 | Endeavor Pharmaceuticals | Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy |
WO2003011282A1 (en) * | 2001-07-31 | 2003-02-13 | Pfizer Products Inc. | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
EP1418920A1 (en) * | 2001-07-27 | 2004-05-19 | Vivus, Inc. | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
EP1420795A1 (en) * | 2001-07-27 | 2004-05-26 | Vivus, Inc. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
EP1523328A2 (en) * | 2002-05-24 | 2005-04-20 | The Trustees of The University of Pennsylvania | Methods and compositions for inhibiting hiv replication |
WO2005110358A2 (en) * | 2004-05-14 | 2005-11-24 | Hf Arzneimittelforschung Gmbh | Film-shaped estriol-containing medicament for oral administration |
WO2010089078A1 (en) * | 2009-02-05 | 2010-08-12 | Bayer Schering Pharma Aktiengesellschaft | Buccal application system comprising 17α-estradiol |
EP2338475A3 (en) * | 2001-11-05 | 2012-08-08 | Orahealth Corporation | Treating canker sores with patches to speed healing and relieve pain |
EP3106148A1 (en) * | 2015-06-18 | 2016-12-21 | Mithra Pharmaceuticals S.A. | Orodispersible dosage unit containing an estetrol component |
WO2016203006A1 (en) * | 2015-06-18 | 2016-12-22 | Mithra Pharmaceuticals S.A. | Orodispersible dosage unit containing an estetrol component |
US10844088B2 (en) | 2011-07-19 | 2020-11-24 | Estetra Sprl | Process for the preparation of estetrol |
US10888518B2 (en) | 2015-06-18 | 2021-01-12 | Estetra Sprl | Orodispersible tablet containing estetrol |
US10894014B2 (en) | 2015-06-18 | 2021-01-19 | Estetra Sprl | Orodispersible tablet containing Estetrol |
US11053274B2 (en) | 2011-06-01 | 2021-07-06 | Estetra S.P.R.L. | Process for the production of estetrol intermediates |
US11053273B2 (en) | 2011-06-01 | 2021-07-06 | Estetra S.P.R.L. | Process for the production of estetrol intermediates |
US11452733B2 (en) | 2018-04-19 | 2022-09-27 | Estetra Sprl | Compounds and their uses for alleviating menopause-associated symptoms |
US11484539B2 (en) | 2018-04-19 | 2022-11-01 | Estetra Sprl | Compounds and their uses for alleviating menopause-associated symptoms |
US11896602B2 (en) | 2016-08-05 | 2024-02-13 | Estetra Srl | Method for preventing pregnancy |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID27922A (en) * | 1998-06-11 | 2001-05-03 | Endorech Inc | PHARMACICAL COMPOSITION AND USE OF ANDROST-5-ENA-3β, 17β-DIOL |
US20030060425A1 (en) * | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
US6544553B1 (en) * | 1999-12-28 | 2003-04-08 | Watson Pharmaceuticals, Inc. | Dosage forms and methods for oral delivery of progesterone |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US20020107230A1 (en) * | 2000-12-22 | 2002-08-08 | Waldon R. Forrest | Methods and formulations for the treatment of female sexual dysfunction |
US20030027804A1 (en) * | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
US20060073174A1 (en) * | 2001-08-16 | 2006-04-06 | Access Pharmaceuticals, Inc. | Adherent and erodible film to treat a moist surface of a body tissue |
US6585997B2 (en) | 2001-08-16 | 2003-07-01 | Access Pharmaceuticals, Inc. | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
DE60218881T2 (en) * | 2001-11-15 | 2007-12-20 | Pantarhei Bioscience B.V. | METHOD FOR PREVENTING OR TREATING BENIGNEN GYNECOLOGICAL DISORDER |
WO2003041719A1 (en) * | 2001-11-15 | 2003-05-22 | Pantarhei Bioscience B.V. | Method of contraception in mammalian females and pharmaceutical kit for use in such method |
US6962908B2 (en) * | 2001-12-21 | 2005-11-08 | Warner Chilcott Company Inc. | Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
US6659985B2 (en) | 2002-01-30 | 2003-12-09 | Southern College Of Optometry | Method to use transdermal administration of androgens to the adnexa of the eye |
EP1340503A1 (en) * | 2002-03-01 | 2003-09-03 | CHIESI FARMACEUTICI S.p.A. | Solution aerosol formulation containing esters of 3, 17-dihydroxy oestratriene derivates for pulmonary delivery |
US20030191096A1 (en) * | 2002-04-03 | 2003-10-09 | Leonard Thomas W. | Method of hormonal therapy |
ES2338782T3 (en) * | 2002-09-05 | 2010-05-12 | Pantarhei Bioscience B.V. | ORAL PHARMACEUTICAL COMPOSITION THAT INCLUDES 15-HYDROXITESTOSTERONE AND DERIVATIVES. |
US6967194B1 (en) * | 2002-09-18 | 2005-11-22 | Susan Matsuo | Bio-identical hormones and method of use |
CA2521471A1 (en) * | 2003-04-11 | 2004-10-28 | Barr Laboratories, Inc. | Methods of administering estrogens and progestins |
US7276246B2 (en) * | 2003-05-09 | 2007-10-02 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
US7306812B2 (en) | 2003-05-09 | 2007-12-11 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
EP1624878B1 (en) * | 2003-05-22 | 2006-09-27 | Pantarhei Bioscience B.V. | Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain |
EP1820494B1 (en) * | 2003-06-13 | 2010-01-13 | Skendi Finance, Ltd. | Microparticles consisting of estradiol and cholesterol |
DK1670440T3 (en) * | 2003-09-29 | 2014-07-07 | Novo Nordisk As | HRT formulations |
ES2933479T3 (en) * | 2003-09-29 | 2023-02-09 | Novo Nordisk Healthcare Ag | Improved stability of progestin formulations |
MX2007005098A (en) * | 2004-11-01 | 2008-01-16 | Endorech Inc | Use of androgens to reduce the likelihood of acquiring or to treat skin aging. |
EP1853272A1 (en) * | 2005-02-03 | 2007-11-14 | Duramed Pharmaceuticals, Inc. | Compositions of unconjugated estrogens and methods for their use |
AU2006230820B2 (en) * | 2005-04-08 | 2011-04-14 | Indigo Ridge Pty Ltd | Buccal delivery system |
JP5256425B2 (en) * | 2005-04-08 | 2013-08-07 | リングアル コンセグナ ピーティーワイ エルティーディー | Oral delivery system |
US20070088012A1 (en) * | 2005-04-08 | 2007-04-19 | Woun Seo | Method of treating or preventing type-2 diabetes |
US20060252010A1 (en) * | 2005-05-09 | 2006-11-09 | Sunnen Gerard V | Sodium chloride pad for treatment of dental conditions |
US20080248090A1 (en) * | 2005-05-09 | 2008-10-09 | Sunnen Gerard V | Graduated concentration sodium chloride patches for the treatment of dental conditions |
JP2007037868A (en) * | 2005-08-05 | 2007-02-15 | Transcutaneous Technologies Inc | Transdermal administration device and its controlling method |
SI1937276T1 (en) | 2005-10-12 | 2013-04-30 | Unimed Pharmaceuticals, Llc C/O Abbott Laboratoires 100 Abbott Park Road | Improved testosterone gel and method of use |
JP5449775B2 (en) | 2005-10-19 | 2014-03-19 | チャバフ ピーティーワイ エルティーディー | Reduction of side effects with aromatase inhibitors used to treat breast cancer |
US20080113953A1 (en) * | 2006-06-08 | 2008-05-15 | Warner Chilcott Company, Inc. | Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability |
US20070286819A1 (en) * | 2006-06-08 | 2007-12-13 | Warner Chilcott Company, Inc. | Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability |
ES2659316T3 (en) * | 2006-06-08 | 2018-03-14 | Allergan Pharmaceuticals International Limited | Procedures for administering solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability |
KR20090027755A (en) * | 2006-07-05 | 2009-03-17 | 티티아이 엘뷰 가부시키가이샤 | Delivery device having self-assembling dendritic polymers and method of use thereof |
US20080132475A1 (en) * | 2006-12-05 | 2008-06-05 | Charles Gerald Connor | Treatment for dry eye |
TW200840595A (en) * | 2006-12-12 | 2008-10-16 | Organon Nv | Oral contraceptive spray |
EP2044943A1 (en) * | 2007-10-04 | 2009-04-08 | Solvay Pharmaceuticals, Inc. | Pharmaceutical compositions comprising esterified estrogens and methyltestosterone and method of using the same |
CN101157729B (en) * | 2007-10-23 | 2011-01-12 | 南京大学 | Tumour putrescence gene related apoptosis ligand variant and uses thereof |
US20090117184A1 (en) * | 2007-11-05 | 2009-05-07 | Sabine Fricke | Use of a gestagen in combination with an estrogen and one or more pharmaceutically acceptable auxiliary agents/excipients for lactose-free oral contraception |
US20100016264A1 (en) * | 2007-12-05 | 2010-01-21 | Connor Charles G | Treatment for dry eye using testosterone and progestagen |
AU2009240586A1 (en) * | 2008-04-24 | 2009-10-29 | Evestra, Inc. | Oral contraceptive dosage forms comprising a progestogen dispersed in an enteric polymer and further comprising an estrogen |
US20110250274A1 (en) * | 2008-09-19 | 2011-10-13 | Shaked Ze Ev | Estriol formulations |
EP2504019A2 (en) | 2009-11-25 | 2012-10-03 | ArisGen SA | Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion |
ES2885523T3 (en) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
WO2017100378A2 (en) * | 2015-12-07 | 2017-06-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
RU2715714C2 (en) | 2013-03-04 | 2020-03-03 | Безен Хелткэа Люксембург Сарл | Dry pharmaceutical compositions containing nanoparticles of active agent bound to carrier particles |
ES2655076T3 (en) | 2013-12-12 | 2018-02-16 | Donesta Bioscience B.V. | Solid dosing unit for oral disintegration with an estetrol component |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
AU2015336929B2 (en) | 2014-10-22 | 2021-03-18 | Havah Therapeutics Pty Ltd | Methods of reducing mammographic breast density and/or breast cancer risk |
US9844558B1 (en) | 2015-04-30 | 2017-12-19 | Amag Pharmaceuticals, Inc. | Methods of reducing risk of preterm birth |
AU2016258179B2 (en) | 2015-05-06 | 2021-07-01 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10556922B2 (en) | 2015-09-29 | 2020-02-11 | Amag Pharmaceuticals, Inc. | Crystalline and amorphous forms of 17-alpha-hydroxyprogesterone caproate |
AU2016343297A1 (en) | 2015-10-22 | 2018-05-10 | Havah Therapeutics Pty Ltd | Methods of reducing mammographic breast density and/or breast cancer risk |
WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US20180207177A1 (en) * | 2017-01-23 | 2018-07-26 | Government Of The United States As Represented By The Secretary Of The Air Force | TREATMENT OF TRIPLE NEGATIVE BREAST CANCER UTILIZING ANDROST-5-ENE-3b,17b-DIOL (b-AED), ANDROST-5-ENE-3b,7b,17b-TRIOL (b-AET) AND ESTRADIOL (E2) |
US10285998B1 (en) | 2018-04-04 | 2019-05-14 | The Menopause Method, Inc. | Composition and method to aid in hormone replacement therapy |
US11813354B1 (en) | 2019-01-11 | 2023-11-14 | Shear Kershman Laboratories, Inc | Trans-mucosal delivery system for testosterone |
EP3976048A4 (en) | 2019-06-03 | 2023-07-12 | Havah Therapeutics Pty Ltd | Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4507323A (en) | 1984-07-25 | 1985-03-26 | Burroughs Wellcome Co. | Treatment of psychosexual dysfunctions |
US4521421A (en) | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
US4764378A (en) | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
US4877774A (en) | 1987-09-09 | 1989-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Administration of steroid hormones |
US5135752A (en) | 1988-10-14 | 1992-08-04 | Zetachron, Inc. | Buccal dosage form |
US5190967A (en) | 1990-06-05 | 1993-03-02 | Glaxo Group Limited | Medicaments for treating erectile disorders |
US5543154A (en) * | 1991-12-27 | 1996-08-06 | Merck & Co., Inc. | Controlled release nifedipine delivery device |
US5639743A (en) | 1992-11-13 | 1997-06-17 | University Of Georgia Research Foundation | Compositions and methods for treating exocrine gland atrophy |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5346701A (en) * | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
US5770226A (en) * | 1996-07-10 | 1998-06-23 | Wake Forest University | Combined pharmaceutical estrogen-androgen-progestin oral contraceptive |
US6653297B1 (en) * | 1997-07-03 | 2003-11-25 | Medical College Of Hampton Roads | Control of selective estrogen receptor modulators |
US6180682B1 (en) | 1999-01-26 | 2001-01-30 | Virgil A. Place | Buccal drug delivery system for use in male contraception |
-
1999
- 1999-01-26 US US09/237,713 patent/US6117446A/en not_active Expired - Fee Related
-
2000
- 2000-01-21 WO PCT/US2000/001546 patent/WO2000042955A1/en not_active Application Discontinuation
- 2000-01-21 AU AU25139/00A patent/AU2513900A/en not_active Abandoned
- 2000-01-21 EP EP00903386A patent/EP1150629A4/en not_active Withdrawn
- 2000-01-21 CA CA002359587A patent/CA2359587A1/en not_active Abandoned
- 2000-07-27 US US09/626,931 patent/US6241529B1/en not_active Expired - Fee Related
- 2000-07-27 US US09/626,772 patent/US6284263B1/en not_active Expired - Fee Related
- 2000-07-27 US US09/626,927 patent/US6200593B1/en not_active Expired - Fee Related
- 2000-07-27 US US09/626,773 patent/US6221379B1/en not_active Expired - Fee Related
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4521421A (en) | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
US4507323A (en) | 1984-07-25 | 1985-03-26 | Burroughs Wellcome Co. | Treatment of psychosexual dysfunctions |
US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
US4764378A (en) | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
US4877774A (en) | 1987-09-09 | 1989-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Administration of steroid hormones |
US5135752A (en) | 1988-10-14 | 1992-08-04 | Zetachron, Inc. | Buccal dosage form |
US5190967A (en) | 1990-06-05 | 1993-03-02 | Glaxo Group Limited | Medicaments for treating erectile disorders |
US5543154A (en) * | 1991-12-27 | 1996-08-06 | Merck & Co., Inc. | Controlled release nifedipine delivery device |
US5639743A (en) | 1992-11-13 | 1997-06-17 | University Of Georgia Research Foundation | Compositions and methods for treating exocrine gland atrophy |
Non-Patent Citations (1)
Title |
---|
See also references of EP1150629A4 * |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002040008A3 (en) * | 2000-11-17 | 2002-08-22 | Warner Lambert Co | Treatment of sexual dysfunction with non peptide bombesin receptor antagonists |
WO2002040008A2 (en) * | 2000-11-17 | 2002-05-23 | Warner-Lambert Company Llc | Treatment of sexual dysfunction with non peptide bombesin receptor antagonists |
AU2002243411B2 (en) * | 2000-12-22 | 2007-02-08 | Barr Laboratories, Inc. | Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy |
WO2002058706A2 (en) * | 2000-12-22 | 2002-08-01 | Endeavor Pharmaceuticals | Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy |
EP2116250A1 (en) * | 2000-12-22 | 2009-11-11 | Barr Laboratories, Inc. | Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy |
WO2002058706A3 (en) * | 2000-12-22 | 2003-03-13 | Endeavor Pharmaceuticals | Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy |
KR100849919B1 (en) * | 2000-12-22 | 2008-08-04 | 바 래버러토리즈, 인코포레이티드 | Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy |
EP1418920A1 (en) * | 2001-07-27 | 2004-05-19 | Vivus, Inc. | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
EP1420795A4 (en) * | 2001-07-27 | 2006-09-06 | Vivus Inc | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
EP1418920A4 (en) * | 2001-07-27 | 2006-10-04 | Vivus Inc | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
EP1420795A1 (en) * | 2001-07-27 | 2004-05-26 | Vivus, Inc. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
WO2003011282A1 (en) * | 2001-07-31 | 2003-02-13 | Pfizer Products Inc. | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
EP2338475A3 (en) * | 2001-11-05 | 2012-08-08 | Orahealth Corporation | Treating canker sores with patches to speed healing and relieve pain |
EP1523328A2 (en) * | 2002-05-24 | 2005-04-20 | The Trustees of The University of Pennsylvania | Methods and compositions for inhibiting hiv replication |
EP1523328A4 (en) * | 2002-05-24 | 2007-10-31 | Univ Pennsylvania | Methods and compositions for inhibiting hiv replication |
WO2005110358A2 (en) * | 2004-05-14 | 2005-11-24 | Hf Arzneimittelforschung Gmbh | Film-shaped estriol-containing medicament for oral administration |
DE102004023984A1 (en) * | 2004-05-14 | 2005-12-08 | Hf Arzneimittelforschung Gmbh | Film-shaped, orally-administered drug containing estriol |
WO2005110358A3 (en) * | 2004-05-14 | 2007-03-15 | Hf Arzneimittelforsch Gmbh | Film-shaped estriol-containing medicament for oral administration |
WO2010089078A1 (en) * | 2009-02-05 | 2010-08-12 | Bayer Schering Pharma Aktiengesellschaft | Buccal application system comprising 17α-estradiol |
DE102009007771B4 (en) * | 2009-02-05 | 2012-02-16 | Bayer Schering Pharma Aktiengesellschaft | Buccal administration system containing 17α-estradiol |
US11053274B2 (en) | 2011-06-01 | 2021-07-06 | Estetra S.P.R.L. | Process for the production of estetrol intermediates |
US11053273B2 (en) | 2011-06-01 | 2021-07-06 | Estetra S.P.R.L. | Process for the production of estetrol intermediates |
US10844088B2 (en) | 2011-07-19 | 2020-11-24 | Estetra Sprl | Process for the preparation of estetrol |
AU2016280863B2 (en) * | 2015-06-18 | 2021-04-01 | Estetra Srl | Orodispersible dosage unit containing an estetrol component |
EA035651B1 (en) * | 2015-06-18 | 2020-07-22 | Эстетра Спрл | Orodispersible dosage unit containing an estetrol component |
JP2021098710A (en) * | 2015-06-18 | 2021-07-01 | エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ | Orodispersible dosage unit containing estetrol component |
US10660903B2 (en) | 2015-06-18 | 2020-05-26 | Estetra Sprl | Orodispersible dosage unit containing an estetrol component |
EP3106148A1 (en) * | 2015-06-18 | 2016-12-21 | Mithra Pharmaceuticals S.A. | Orodispersible dosage unit containing an estetrol component |
EA035687B1 (en) * | 2015-06-18 | 2020-07-27 | Эстетра Спрл | Orodispersible dosage unit containing an estetrol component |
EP3701944A1 (en) * | 2015-06-18 | 2020-09-02 | Estetra SPRL | Orodispersible dosage unit containing an estetrol component |
WO2016203006A1 (en) * | 2015-06-18 | 2016-12-22 | Mithra Pharmaceuticals S.A. | Orodispersible dosage unit containing an estetrol component |
US10888518B2 (en) | 2015-06-18 | 2021-01-12 | Estetra Sprl | Orodispersible tablet containing estetrol |
US10894014B2 (en) | 2015-06-18 | 2021-01-19 | Estetra Sprl | Orodispersible tablet containing Estetrol |
WO2016203011A1 (en) * | 2015-06-18 | 2016-12-22 | Mithra Pharmaceuticals S.A. | Orodispersible dosage unit containing an estetrol component |
AU2016280858B2 (en) * | 2015-06-18 | 2021-06-24 | Estetra Srl | Orodispersible dosage unit containing an estetrol component |
JP2018521985A (en) * | 2015-06-18 | 2018-08-09 | ミトラ ファーマシューティカルズ エス.エー.Mithra Pharmaceuticals S.A. | Orally disintegrating dosage unit containing estetrol component |
CN107787224A (en) * | 2015-06-18 | 2018-03-09 | 密特拉制药公司 | The orodispersible dosage unit of the component containing E4 |
IL256282A (en) * | 2015-06-18 | 2018-02-28 | Jan Platteeuw Johannes | Orodispersible dosage unit containing an estetrol component |
US11147771B2 (en) | 2015-06-18 | 2021-10-19 | Estetra Sprl | Orodispersible dosage unit containing an estetrol component |
JP7140355B2 (en) | 2015-06-18 | 2022-09-21 | エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ | An orally disintegrating dosage unit containing an estetrol component |
US11964055B2 (en) | 2015-06-18 | 2024-04-23 | Estetra Srl | Orodispersible dosage unit containing an estetrol component |
US11957694B2 (en) | 2015-06-18 | 2024-04-16 | Estetra Srl | Orodispersible dosage unit containing an estetrol component |
AU2022283615B2 (en) * | 2015-06-18 | 2023-11-23 | Estetra Srl | Orodispersible dosage unit containing an estetrol component |
US11793760B2 (en) | 2015-06-18 | 2023-10-24 | Estetra Srl | Orodispersible dosage unit containing an estetrol component |
US11896602B2 (en) | 2016-08-05 | 2024-02-13 | Estetra Srl | Method for preventing pregnancy |
US11666585B2 (en) | 2018-04-19 | 2023-06-06 | Estetra Srl | Compounds and their uses for alleviating menopause-associated symptoms |
US11484539B2 (en) | 2018-04-19 | 2022-11-01 | Estetra Sprl | Compounds and their uses for alleviating menopause-associated symptoms |
US11452733B2 (en) | 2018-04-19 | 2022-09-27 | Estetra Sprl | Compounds and their uses for alleviating menopause-associated symptoms |
Also Published As
Publication number | Publication date |
---|---|
EP1150629A4 (en) | 2005-03-16 |
US6241529B1 (en) | 2001-06-05 |
AU2513900A (en) | 2000-08-07 |
EP1150629A1 (en) | 2001-11-07 |
CA2359587A1 (en) | 2000-07-27 |
US6284263B1 (en) | 2001-09-04 |
US6200593B1 (en) | 2001-03-13 |
US6117446A (en) | 2000-09-12 |
US6221379B1 (en) | 2001-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6117446A (en) | Drug dosage unit for buccal administration of steroidal active agents | |
US6284262B1 (en) | Compact dosage unit for buccal administration of a pharmacologically active agent | |
US6180682B1 (en) | Buccal drug delivery system for use in male contraception | |
AU2004220498B2 (en) | Uses and formulations for transdermal or transmucosal application of active agents | |
JP5184727B2 (en) | Parenteral androgenic steroid administration to women | |
US20020013304A1 (en) | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness | |
JP4945052B2 (en) | Methods and formulations for treating female sexual dysfunction | |
US7226910B2 (en) | Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists | |
US20050070516A1 (en) | As-needed administration of an androgenic agent to enhance female desire and responsiveness | |
US20030022875A1 (en) | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness | |
JP2014074060A (en) | Oral modified release formulation | |
KR20070067248A (en) | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive | |
MXPA06012890A (en) | Film-shaped estriol-containing medicament for oral administration. | |
Watkinson | The pharmacokinetics of drug delivery systems in hormone replacement therapy | |
AU2002313709A1 (en) | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness | |
AU2002313708A1 (en) | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2359587 Country of ref document: CA Ref country code: CA Ref document number: 2359587 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000903386 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000903386 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000903386 Country of ref document: EP |